Most non-small-cell lungcancer is caused by smoking, but your genes may also help determine your chances of getting the disease. Lung cancer is when cell growth in the lungs becomes abnormal and ...

(Reuters) -BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks BioNTech SE ( (BNTX) ) has provided an update.

Cibisatamab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer.

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Incyte (NASDAQ:INCY) reported positive results from a Phase 3 study of its drug Zynyz in the treatment of non-small cell lung cancer ... previously untreated non-squamous and squamous metastatic ...

BioNTech (BNTX) said it has been informed by its partner OncoC4 that the Food and Drug Administration has lifted the partial clinical hold on ...

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery. Amivantamab's role in non–small cell lung ...

Rilvegostomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer.